Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Preliminary findings in mCRPC for fractionated dose 177Lu-PSMA-617

Scott Tagawa • 27 Sep 2019
ESMO 2019
Genitourinary Cancer Prostate Cancer

Scott Tagawa, MD, MS, Weill Cornell Medicine, New York, NY, discusses the initial findings of the trial of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC; NCT03042468). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Scott Tagawa

1:41
PSMAddition: 177Lu-PSMA-617 plus standard of care vs SoC alone in patients with mHSPC
Scott Tagawa • 3 Jun 2023
2:57
Efficacy of sacituzumab govitecan in mUC by Trop-2 expression
Scott Tagawa • 3 Jun 2023
1:51
Future directions in the field of targeted therapies for urothelial carcinoma
Scott Tagawa • 3 Jun 2023
3:07
PSMA-TRT, 225Ac-J591 and 177Lu-PSMA I&T in mCRPC
Scott Tagawa • 3 Jun 2023

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals